The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Cytomegalovirus in transplantation – challenging the status quo
Abstract
Background: Cytomegalovirus (CMV) infection of solid organ transplant (SOT) recipients causes both ‘‘direct’’ and ‘‘indirect’’ effects including allograft rejection, decreased graft and patient survival, and predisposition to opportunistic infections and malignancies. Options for CMV prevention include pre‐emptive therapy, whereby anti‐CMV agents are administered based on sensitive viral assays, or universal prophylaxis of all at‐risk patients. Each approach has advantages and disadvantages in terms of efficacy, costs, and side effects. Standards of care for prophylaxis have not been established. Methods: A committee of international experts was convened to review the available data regarding CMV prophylaxis and to compare preventative strategies for CMV after transplantation from seropositive donors or in seropositive recipients. Results: Pre‐emptive therapy requires frequent monitoring with subsequent treatment of disease and associated costs, while universal prophylaxis results in greater exposure to potential toxicities and costs of drugs. The advantages of prophylaxis include suppressing asymptomatic viremia and prevention of both direct and indirect effects of CMV infection. Meta analyses reveal decreased in mortality for patients receiving CMV prophylaxis. Costs associated with prophylaxis are less than for routine monitoring and pre‐emptive therapy. The optimal duration of antiviral prophylaxis remains undefined. Extended prophylaxis may improve clinical outcomes in the highest‐risk patient populations including donor‐seropositive/recipient‐seronegative renal transplants and in CMV‐infected lung and heart transplantation. Conclusions: Prophylaxis is beneficial in preventing direct and indirect effects of CMV infection in transplant recipients, affecting both allograft and patient survival. More studies are necessary to define optimal prophylaxis regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infection in Organ-Transplant Recipients
Fishman, J. A., & Rubin, R. H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806113382407 · Cited by 1,622
Self-citationPaya, C., Humar, A., Dominguez, E., Washburn, K., Blumberg, E., Alexander, B., Freeman, R., Heaton, N., & Pescovitz, M. D. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00382.x · Cited by 880
Self-citationHuman cytomegalovirus infection and expression in human malignant glioma.
Cobbs, C., Harkins, L. E., Samanta, M., Gillespie, G. Y., Bharara, S., King, P. H., Nabors, B., Cobbs, C. G., & Britt, W. J. (2002) · PubMed · Cited by 717
Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation
Lowance, D., Neumayer, H.-H., Legendre, C. M., Squifflet, J.-P., Kovarik, J., Brennan, P. J., Norman, D., Mendez, R., Keating, M. R., Coggon, G. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905133401903 · Cited by 712
Gane, E., Saliba, F., Valdecasas, G. J., O'Grady, J., Pescovitz, M. D., Lyman, S., & Robinson, C. A. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05535-9 · Cited by 496
Kalil, A. C., Levitsky, J., Lyden, E., Stoner, J., & Freifeld, A. G. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-12-200512200-00005 · Cited by 389
Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients
Pescovitz, M. D., Rabkin, J., Merion, R. M., Paya, C. V., Pirsch, J., Freeman, R. B., O'Grady, J., Robinson, C., To, Z., Wren, K., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2811-2815.2000 · Cited by 357
Self-citationHodson, E. M., Jones, C. A., Webster, A. C., Strippoli, G. F., Barclay, P. G., Kable, K., Vimalachandra, D., & Craig, J. C. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66553-1 · Cited by 350
Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer
Harkins, L., Volk, A. L., Samanta, M., Mikolaenko, I., Britt, W. J., Bland, K. I., & Cobbs, C. S. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11524-8 · Cited by 346
SAMANTA, M., HARKINS, L., KLEMM, K., BRITT, W. J., & COBBS, C. S. (2003) · Journal of Urology · doi:10.1097/01.ju.0000080263.46164.97 · Cited by 316
Valantine, H. A., Gao, S.-Z., Menon, S. G., Renlund, D. G., Hunt, S. A., Oyer, P., Stinson, E. B., Brown, B. W., Merigan, T. C., & Schroeder, J. S. (1999) · Circulation · doi:10.1161/01.cir.100.1.61 · Cited by 292
Specific Localisation of Human Cytomegalovirus Nucleic Acids and Proteins in Human Colorectal Cancer
(2003) · Zeitschrift für Gastroenterologie · doi:10.1055/s-2003-41205 · Cited by 292
Mycophenolate Mofetil Dose Reduction and the Risk of Acute Rejection after Renal Transplantation
Knoll, G. A., MacDonald, I., Khan, A., & van Walraven, C. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000079616.71891.f5 · Cited by 287
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients
Hodson, E. M., Ladhani, M., Webster, A. C., Strippoli, G. F., & Craig, J. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003774.pub4 · Cited by 268
Cytomegalovirus (CMV) DNA Load Predicts Relapsing CMV Infection after Solid Organ Transplantation
Sia, I. G., Wilson, J. A., Groettum, C. M., Espy, M. J., Smith, T. F., & Paya, C. V. (2000) · The Journal of Infectious Diseases · doi:10.1086/315242 · Cited by 220
Sommadossi, J. P., & Carlisle, R. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.3.452 · Cited by 186
POUTEIL-NOBLE, C., ECOCHARD, R., LANDRIVON, G., DONIA-MAGED, A., TARDY, J.-C., BOSSHARD, S., COLON, S., BETUEL, H., AYMARD, M., & TOURAINE, J.-L. (1993) · Transplantation · doi:10.1097/00007890-199304000-00032 · Cited by 174
Zamora, M. R., Nicolls, M. R., Hodges, T. N., Marquesen, J., Astor, T., Grazia, T. J., & Weill, D. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00571.x · Cited by 157
A Comparison of Ganciclovir and Acyclovir to Prevent Cytomegalovirus After Lung Transplantation
Duncan, S. R., Grgurich, W. F., Iacono, A. T., Burckart, G. J., Yousem, S. A., Paradis, I. L., Williams, P. A., Johnson, B. A., & GRIFFITH, B. P. (1994) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.150.1.8025741 · Cited by 152
Cytomegalovirus Infection Impairs the Nitric Oxide Synthase Pathway
Weis, M., Kledal, T. N., Lin, K. Y., Panchal, S. N., Gao, S., Valantine, H. A., Mocarski, E. S., & Cooke, J. P. (2004) · Circulation · doi:10.1161/01.cir.0000109692.16004.af · Cited by 149
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
Basgoz, N. O., & Preiksaitis, J. K. (1995) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(20)30708-x · Cited by 124
The Role of Viruses in Cardiac Allograft Vasculopathy
Valantine, H. A. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00316.x · Cited by 106
Effects of human cytomegalovirus infection on the coagulation system
Gerdes, V. E. A., Buller, H. R., & Squizzato, A. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-08-0523 · Cited by 97
Falagas, M. E., Snydman, D. R., Ruthazer, R., et al. (1997) · PubMed · Cited by 79
Opportunistic infections after blood and marrow transplantation
Wingard, J. R. (1999) · Transplant Infectious Disease · doi:10.1034/j.1399-3062.1999.10102.x · Cited by 78
Cytomegalovirus Gene Regulation by Reactive Oxygen Species: Agents in Atherosclerosis
SPEIR, E. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06200.x · Cited by 56
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients
Hodson, E., Barclay, P. G., Craig, J. C., Jones, C., Kable, K., Strippoli, G., Vimalachandra, D., & Webster, A. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003774.pub2 · Cited by 52
Mayer, K. H., Armstrong, W. S., & Kazanjian, P. H. (2001) · Clinical Infectious Diseases · doi:10.1086/319227 · Cited by 27
Importance of CMV in the transplant population.
Rubin, R. H. (1999) · PubMed · Cited by 25
Progress in the Clinical Management of Herpesvirus Infections
Griffiths, P. D. (1995) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029500600401 · Cited by 20
Cited by
Lopez-Vergès, S., Milush, J. M., Schwartz, B. S., Pando, M. J., Jarjoura, J., York, V. A., Houchins, J. P., Miller, S., Kang, S.-M., Norris, P. J., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110900108 · Cited by 822
Temporal Response of the Human Virome to Immunosuppression and Antiviral Therapy
De Vlaminck, I., Khush, K. K., Strehl, C., Kohli, B., Luikart, H., Neff, N. F., Okamoto, J., Snyder, T. M., Cornfield, D. N., Nicolls, M. R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.10.034 · Cited by 471
Imaging of Pulmonary Viral Pneumonia
Franquet, T. (2011) · Radiology · doi:10.1148/radiol.11092149 · Cited by 380
Cytomegalovirus: pathogen, paradigm, and puzzle
Boeckh, M., & Geballe, A. P. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45449 · Cited by 357
Manifestations of Human Cytomegalovirus Infection: Proposed Mechanisms of Acute and Chronic Disease
Britt, W. (2008) · Current Topics in Microbiology and Immunology · doi:10.1007/978-3-540-77349-8_23 · Cited by 345
Metadata
- Authors
- Fishman, J. A., Emery, V., Freeman, R., Pascual, M., Rostaing, L., Schlitt, H. J., Sgarabotto, D., Torre‐Cisneros, J., & Uknis, M. E.
- Venue
- Clinical Transplantation
- Publisher
- Wiley
- Published
- 2007-03
- Volume
- 21
- Issue
- 2
- Pages
- 149-158
- ISSN
- 0902-0063 (ISSN-L)
- 1399-0012
- OpenAlex
- W2026145100
- Cited by
- 289
- References
- 30
- FWCI
- 13.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.